Elevance Health reported past third quarter 2026 adjusted EPS of $6.99, above prior estimates, raised its 2026 EPS outlook to at least $29, and reiterated an expectation for at least 12% adjusted EPS growth in 2027, while medical membership declined 1.1%.
The new CMS CRUSH proposal on Medicare Advantage repayments, with projected recoveries of about US$90.2b across the sector, directly tests Elevance Health’s ability to manage Medicare margins and long term earnings quality despite stronger contributions from CarelonRx and Carelon Services.
We will now look at how Elevance Health’s investment narrative holds up against the CMS CRUSH Medicare Advantage repayment proposal shock.
Scan how Elevance Health’s Medicare headlines compare with other defensive insurers by zeroing in on 32 resilient stocks with low risk scores, which is positioned to weather regulatory shocks.
Elevance Health Investment Narrative Recap
To stay invested in Elevance Health, you need to be comfortable with a story built around disciplined medical cost control and shifting more earnings toward CarelonRx and Carelon Services. The recent Q3 2026 beat and higher 2026 EPS outlook lean on that narrative, while the CMS CRUSH proposal puts a spotlight on how resilient Medicare Advantage profitability really is.
Right now, the key near term catalyst is management’s ability to hold its at least 12% adjusted EPS growth expectation for 2027 in the face of the new Medicare repayment overhang. The biggest risk is that elevated medical cost trends and any CRUSH related repayments could squeeze benefit ratios faster than Carelon’s services profit pool can support the earnings baseline.
The most relevant update is Elevance Health’s decision to lift its 2026 adjusted EPS target to at least US$29 after reporting US$6.99 in Q3 EPS. That step raises the earnings base that the analyst consensus Narrative on Simply Wall St already used and makes any CRUSH related margin pressure more visible against a higher bar.
This higher earnings floor connects directly to the existing catalysts around tighter cost management through HealthOS and Sydney Health, as well as efforts to improve Medicare Advantage margins. If medical membership softness, Medicaid pressure and Medicare repayments all occur at the same time, the execution test becomes whether CarelonRx, Carelon Services and AI driven cost programs can keep that upgraded outlook intact.
Elevance Health’s narrative points to revenues of US$211.4b and earnings of US$7.6b by 2029, based on analysts assuming about 1.5% yearly revenue growth and an earnings increase of roughly US$2.5b from the current US$5.1b base.
Source: finance.yahoo.com



